A Phase 1, Single Centre Randomised, Double-blind Placebo-controlled Multiple Dose Study With Incremental Dosing to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Doses of LEO 32731 in Healthy Male Japanese Subjects.
Latest Information Update: 28 Aug 2017
At a glance
- Drugs Orismilast (Primary)
- Indications Plaque psoriasis
- Focus Pharmacokinetics
- Sponsors LEO Pharma
- 24 Aug 2017 Status changed from recruiting to completed.
- 01 Aug 2017 New trial record